Rapid, ultrasensitive and highly specific biosensor for the diagnosis of SARS-CoV-2 in clinical blood samples

Zeng, Lu; Li, Yue; Liu, Jie; Guo, Lingling; Wang, Zhongxing; Xu, Xinxin; Song, Shanshan; Hao, Changlong; Liu, Liqiang; Xin, Meiguo; Xu, Chuanlai

doi:10.1039/d0qm00294a

Cited by 63 publications

(64 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, new diagnostic sensors( Xu et al, 2020 ) have been developed to support the standard SARS-CoV-2 diagnostic techniques by detecting the viral RNA by using CRISPR (clustered regularly interspaced short palindromic repeats) based assays( Huang et al, 2020 ) and plasmonics( Qiu et al, 2020 ), the viral surface proteins by field-effect transistors( Seo et al, 2020 ), membrane-engineered mammalian cells( Mavrikou et al, 2020 ), and toroidal plasmonic devices( Ahmadivand et al, 2020 ). In addition, new lateral flow assays based on immunochromatographic strips have also been established to identify the antibodies produced in blood in response to the viral infection with qualitative outputs (i.e.,positive or negative)( Zeng et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Detection of antibodies against SARS-CoV-2 spike protein by gold nanospikes in an opto-microfluidic chip

Funari

Chu

Shen

2020

Biosensors and Bioelectronics

237

217

View full text Add to dashboard Cite

The ongoing global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to active research in its associated diagnostics and medical treatments. While quantitative reverse transcription polymerase chain reaction (qRT-PCR) is the most reliable method to detect viral genes of SARS-CoV-2, serological tests for specific antiviral antibodies are also important as they identify false negative qRT-PCR responses, track how effectively the patient’s immune system is fighting the infection, and are potentially helpful for plasma transfusion therapies. In this work, based on the principle of localized surface plasmon resonance (LSPR), we develop an opto-microfluidic sensing platform with gold nanospikes, fabricated by electrodeposition, to detect the presence and amount of antibodies specific to the SARS-CoV-2 spike protein in 1 L of human plasma diluted in 1mL of buffer solution, within 30min. The target antibody concentration can be correlated with the LSPR wavelength peak shift of gold nanospikes caused by the local refractive index change due to the antigen–antibody binding. This label-free microfluidic platform achieves a limit of detection of 0.08ng/mL ( 0.5pM), falling under the clinical relevant concentration range. We demonstrate that our opto-microfluidic platform offers a promising point-of-care testing tool to complement standard serological assays and make SARS-CoV-2 quantitative diagnostics easier, cheaper, and faster.

show abstract

Section: Introductionmentioning

confidence: 99%

Detection of antibodies against SARS-CoV-2 spike protein by gold nanospikes in an opto-microfluidic chip

Funari

Chu

Shen

2020

Biosensors and Bioelectronics

237

217

View full text Add to dashboard Cite

show abstract

“… 11 , 12 Testing of specific immunoglobulin M (IgM) and immunoglobulin G (IgG) against SARS-CoV-2 in human serum is an alternative way to diagnose COVID-19. 13 , 14 Several serological immunoassays, such as lateral flow immunoassay, 15 − 18 enzyme-linked immunosorbent assay (ELISA), 19 and automated chemiluminescent immunoassay, 12 , 20 have been developed for the detection of IgM and IgG.…”

mentioning

confidence: 99%

Early Detection of SARS-CoV-2 Seroconversion in Humans with Aggregation-Induced Near-Infrared Emission Nanoparticle-Labeled Lateral Flow Immunoassay

Ren²,

et al. 2021

View full text Add to dashboard Cite

An outbreak of coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses great threats to human health and the international economy. To reduce large-scale infection and transmission risk of SARS-CoV-2, a simple, rapid, and sensitive serological diagnostic method is urgently needed. Herein, an aggregation-induced emission (AIE) nanoparticle (AIE810NP, λem = 810 nm)-labeled lateral flow immunoassay was designed for early detection of immunoglobulin M (IgM) and immunoglobulin G (IgG) against SARS-CoV-2 in clinical serum samples. Using a near-infrared (NIR) AIE nanoparticle as the fluorescent reporter (△λ = 145 nm), the autofluorescence from the nitrocellulose membrane and biosample and the excitation background noise were effectively eliminated. After optimization, the limit of detection of IgM and IgG is 0.236 and 0.125 μg mL–1, respectively, commensurate with that of the enzyme-linked immunosorbent assay (ELISA) (0.040 and 0.039 μg mL–1). The sensitivity of the proposed AIE810NP-based test strip for detecting IgM and IgG is 78 and 95% (172 serum samples), commensurate with that of ELISA (85 and 95%) and better than that of a commercial colloidal gold nanoparticle (AuNP)-based test strip (41 and 85%). Importantly, the time of detecting IgM or IgG with an AIE810NP-based test strip in sequential clinical samples is 1–7 days after symptom onset, which is significantly earlier than that with a AuNP-based test strip (8–15 days). Therefore, the NIR-emissive AIE nanoparticle-labeled lateral flow immunoassay holds great potential for early detection of IgM and IgG in a seroconversion window period.

show abstract

“…The sensitivity improved to 85.29% when both antibodies are present in the sample. 74 In another report, the colloidal gold nanoparticles conjugated with SARS-CoV-2 spike the antibody-based toroidal plasmonic metasensor described. They have detected up to femtomolar levels (LOD ∼ 4.2 fM) of SARS-CoV-2.…”

Section: Optical Lateral Flow Immunoassay-based Point-of-care Diagnosmentioning

confidence: 99%

Point-of-Care Biosensor-Based Diagnosis of COVID-19 Holds Promise to Combat Current and Future Pandemics

Parihar

Ranjan

Sanghi

et al. 2020

ACS Appl. Bio Mater.

138

107

View full text Add to dashboard Cite

Efficient and rapid detection of viruses plays an extremely important role in disease prevention, diagnosis, and environmental monitoring. Early screening of viral infection among the population has the potential to combat the spread of infection. However, the traditional methods of virus detection being used currently, such as plate culturing and quantitative RT-PCR, give promising results, but they are time-consuming and require expert analysis and costly equipment and reagents; therefore, they are not affordable by people in low socio-economic groups in developing countries. Further, mass or bulk testing chosen by many governments to tackle the pandemic situation has led to severe shortages of testing kits and reagents and hence are affecting the demand and supply chain drastically. We tried to include all the reported current scenario-based biosensors such as electrochemical, optical, and microfluidics, which have the potential to replace mainstream diagnostic methods and therefore could pave the way to combat COVID-19. Apart from this, we have also provided information on commercially available biosensors for detection of SARS-CoV-2 along with the challenges in development of better diagnostic approaches. It is therefore expected that the content of this review will help researchers to design and develop more sensitive advanced commercial biosensor devices for early diagnosis of viral infection, which can open up avenues for better and more specific therapeutic outcomes.

show abstract

Rapid, ultrasensitive and highly specific biosensor for the diagnosis of SARS-CoV-2 in clinical blood samples

Abstract:
IgG–IgM immunochromatographic strip for rapid screening of SARS-CoV-2 infection including confirmed patients, suspect and asymptomatic carriers in 15 min.

Cited by 63 publications

References 27 publications

Detection of antibodies against SARS-CoV-2 spike protein by gold nanospikes in an opto-microfluidic chip

Detection of antibodies against SARS-CoV-2 spike protein by gold nanospikes in an opto-microfluidic chip

Early Detection of SARS-CoV-2 Seroconversion in Humans with Aggregation-Induced Near-Infrared Emission Nanoparticle-Labeled Lateral Flow Immunoassay

Point-of-Care Biosensor-Based Diagnosis of COVID-19 Holds Promise to Combat Current and Future Pandemics

Contact Info

Product

Resources

About

Rapid, ultrasensitive and highly specific biosensor for the diagnosis of SARS-CoV-2 in clinical blood samples

Abstract: IgG–IgM immunochromatographic strip for rapid screening of SARS-CoV-2 infection including confirmed patients, suspect and asymptomatic carriers in 15 min.

Cited by 63 publications

References 27 publications

Detection of antibodies against SARS-CoV-2 spike protein by gold nanospikes in an opto-microfluidic chip

Detection of antibodies against SARS-CoV-2 spike protein by gold nanospikes in an opto-microfluidic chip

Early Detection of SARS-CoV-2 Seroconversion in Humans with Aggregation-Induced Near-Infrared Emission Nanoparticle-Labeled Lateral Flow Immunoassay

Point-of-Care Biosensor-Based Diagnosis of COVID-19 Holds Promise to Combat Current and Future Pandemics

Contact Info

Product

Resources

About

Abstract:
IgG–IgM immunochromatographic strip for rapid screening of SARS-CoV-2 infection including confirmed patients, suspect and asymptomatic carriers in 15 min.